13F Holdings
中文EN

APVO Aptevo Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671584 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY4.0%
TTM EPS YoY100.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-239.1%
ROA-125.9%
ROIC (approx.)-1,145.2%
Asset turnover—

Leverage & solvency

Liabilities / assets71.1%
Debt / equity0.00x
Current ratio1.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$3.11M$12.29M
R&D expense$14.54M$14.38M$17.11M$17.88M$18.99M
SG&A expense$11.77M$10.22M$11.77M$13.87M$14.70M
Operating income-$26.31M-$24.60M-$28.88M-$28.64M-$21.40M
Pretax income-$25.97M-$24.13M-$18.65M$7.01M-$29.41M
Income tax$0————
Net income-$25.97M-$24.13M-$17.41M$8.03M-$28.46M
EBITDA-$26.07M-$24.25M-$28.31M-$27.74M-$20.26M
EPS (basic)-87.27-31,460.23-2,316.831.57-6.07
EPS (diluted)-87.27-31,460.23-2,316.831.57-6.07
Weighted avg. shares (diluted)315,5357677,5155.10M4.69M
Balance sheet
Cash & equivalents$21.62M$8.71M$16.90M$22.64M$45.04M
Current assets$23.08M$10.66M$19.07M$27.45M$52.57M
PP&E, net$303,000$543,000$895,000$1.46M$2.38M
Total assets$27.19M$15.59M$24.84M$34.22M$56.60M
Current liabilities$6.05M$6.21M$7.22M$8.71M$34.76M
Short-term debt———$2.00M$11.67M
Long-term debt——$0$1.46M$3.71M
Total debt——$0$3.46M$15.37M
Total liabilities$9.81M$10.84M$12.62M$16.24M$55.38M
Shareholders' equity$17.38M$4.75M$12.22M$17.97M$1.22M
Net debt——-$16.90M-$19.18M-$29.67M
Shares outstanding997,8304,05111,9586.47M4.90M
Cash flow statement
Operating cash flow-$25.59M-$23.79M-$11.73M-$21.02M-$21.68M
Capital expenditure———$29,000$713,000
Free cash flow———-$21.05M-$22.39M
Investing cash flow$0$0$0-$29,000-$713,000
Financing cash flow$38.50M$15.60M$6.00M-$2.62M$26.16M
Depreciation & amortization$240,000$352,000$567,000$901,000$1.14M
Stock-based compensation$96,000$1.07M$2.19M$1.80M$1.64M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.